The annual meeting of Diabetes UK (formerly British Diabetic Association) took place in Liverpool in the first week of March. As it is the annual meeting of the association it is considered one of the largest gathering of diabetes health care professionals in United Kingdom and Europe. It attracts diabetes physicians from around the globe. The meeting had plenary sessions which focused new agents, basic science and clinical aspects of diabetes. There was strong focus on the use of technologies in the management of diabetes specially insulin pumps and closed loops systems. The named Lectures was delivered by leading names in the field. The session on new insulin was delivered by Dr Russell-Jones from Guildford, Surry. Dr Russell-Jones elaborated on long acting insulin. Of these, the recently launched insulin Degludec (by Novo-Nordisk) which has a half life (t1/2) of 25 hours (insulin glarging t1/2 is 12 hours), has a more flat pharmacokinetics it proves to be convenient for patients which could be given any time of the day with no rigid adherence to the same time of use as with glargine, more safe (compared with glargine) having less incidence of nocturnal hypos and less no excess hypos and having an HbA1c reduction similar to glargine. The second long acting insulin which is currently in phase 3 trials is U300 glargine by Sanofi. It has the same molecular weight of the conventional glargine, but it has more flat pharmacokinetic profile that lasts longer, with less overall hypos and less nocturnal hypos. It is expected to be launched early in 2015.